Ongoing Clinical Studies in Bladder Cancer

Cretostimogene grenadenorepvec (CG0070) is currently being evaluated in multiple studies including Phase 1b/2, Phase 2, and Phase 3 studies in the U.S. in BCG unresponsive NMIBC and MIBC. Two studies are actively recruiting. Studies are on-going in South Korea, Japan, China, Taiwan, Australia, and Canada.

Trial Title Trial Number Stage Status Publication

BOND-002

Safety and Efficacy

NCT02365818

Phase 2, US only

Completed

Phase 2 publication interim results

BOND-003

Phase 3

NCT04452591

Phase 3, Global (US, Japan, South Korea, Taiwan, Australia, Canada)

Recruiting

Phase 2 publication interim results

CORE-001

Phase 2, CG0070 Combined With Pembrolizumab

NCT04387461

Phase 2, Global (US, South Korea)

Active, Not Recruiting

Phase 2 interim data (ASCO 2022)

CORE-002

Phase 1 Study With Nivolumab Ineligible Cisplatin with MIBC

NCT04610671

Phase 1b/2, US Only

Recruiting

Phase 1b/2 interim data (ASCO 2022):

Patients and Urologists interested in participating should contact:

JoAnn Horn
phone: 516-456-1415
joann.horn@CGOncology.com.

Partners

CG Oncology is eager to partner with companies who share our passion for improving patients and their loved one’s lives. Collaborations could be in R&D, business development or clinical trials. Our partners include:

  • Merck
  • Bristol Myers Squibb
  • Roche
  • Kissei Pharmaceutical Co.
  • LEPU Medical Holdings
  • FUJIFILM Diosynth Biotechnologies
     

If you are interested in becoming a partner with us, please contact us at bd@cgoncology.com